Niranjan Y. Sardesai
Chief Executive Officer at Geneos Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lota Zoth | F | 64 | 6 years | |
| Wendy Yarno | F | 68 | 7 years | |
| Laurent Humeau | M | 57 |
Geneos Therapeutics, Inc.
 Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | 10 years |
| Joann Peters | F | - |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | 5 years |
| Samuel Broder | M | 79 |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | - |
| W. Jeffrey Allard | M | - |
Fujirebio Diagnostics, Inc.
 Fujirebio Diagnostics, Inc. Medical SpecialtiesHealth Technology Fujirebio Diagnostics, Inc. develops, manufactures and commercializes in-vitro diagnostic products. Its products include oncology RIA and EIA kits, veterinary products and research kits. The company was founded in 1965 and is headquartered in Malvern, PA | 20 years |
| Monte W. Wiltse | M | - |
Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics, Inc. Medical SpecialtiesHealth Technology Fujirebio Diagnostics, Inc. develops, manufactures and commercializes in-vitro diagnostic products. Its products include oncology RIA and EIA kits, veterinary products and research kits. The company was founded in 1965 and is headquartered in Malvern, PA | 19 years |
| Omar Khalil | M | - |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | 1 years |
| Mark C. Twyman | M | 63 | 6 years | |
| Shawn Tomasello | F | 65 |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | - |
| Sang-Woo Lee | M | - |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | 3 years |
| Jeffrey Skolnik | M | - | 8 years | |
| Ted Ingemar Jakob Fjällman | M | 46 |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | 2 years |
| Shawn D. Bridy | M | - | 6 years | |
| Sangwoo Lee | M | 52 |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| J. Kim | M | 55 |
VGX Pharmaceuticals LLC
 VGX Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology VGX Pharmaceuticals LLC develops pharmaceuticals. The company was founded by J. Joseph Kim and is headquartered in Blue Bell, PA. | 22 years |
| Keith H. Wells | M | 64 |
VGX Pharmaceuticals LLC
VGX Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology VGX Pharmaceuticals LLC develops pharmaceuticals. The company was founded by J. Joseph Kim and is headquartered in Blue Bell, PA. | 4 years |
| Morton Collins | M | 88 |
VGX Pharmaceuticals LLC
VGX Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology VGX Pharmaceuticals LLC develops pharmaceuticals. The company was founded by J. Joseph Kim and is headquartered in Blue Bell, PA. | 12 years |
| Angel Cabrera | M | 56 | 8 years | |
| Thomas S. Kim | M | - | 10 years | |
| Nancy Wysenski | F | 66 | 2 years | |
| Punit Dhillon | M | 44 | 8 years | |
| Adel Mahmoud | M | 82 | - | |
| George Bickerstaff | M | 68 | 1 years | |
| Avtar Dhillon | M | 62 | 18 years | |
| Tazdin Esmail | M | 75 | 1 years | |
| Feng Lin | M | 54 | 6 years | |
| Ben Matone | M | - | - | |
| Paul Stead | M | - | - | |
| Ami Shah Brown | M | - | 11 years | |
| Scott M. White | M | - | 4 years | |
| Jennifer Laux | F | - | 5 years | |
| Riaz Bandali | M | 55 | 5 years | |
| Jeffrey C. Richardson | M | - | - | |
| Iacob Mathiesen | M | 57 | - | |
| Mark Bagarazzi | M | 63 | 9 years | |
| David J. Williams | M | 74 | 2 years | |
| Kevin Rassas | M | 77 | 3 years | |
| C. Jo White | M | 69 | - | |
| Yoshihiro Ashihara | M | 70 |
Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics, Inc. Medical SpecialtiesHealth Technology Fujirebio Diagnostics, Inc. develops, manufactures and commercializes in-vitro diagnostic products. Its products include oncology RIA and EIA kits, veterinary products and research kits. The company was founded in 1965 and is headquartered in Malvern, PA | - |
| Patrick Gan | M | 66 | 1 years | |
| Robert W. Rieder | M | 78 | 2 years | |
| Abdelhakim Hammach | M | - |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | 1 years |
| Zane Yang | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 44 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Niranjan Y. Sardesai
- Personal Network
